Neurodegenerative Diseases
Glia Protects Neurons against Extracellular Human NeuromelaninDepboylu C.a · Matusch A.b · Tribl F.c · Zoriy M.b · Michel P.P.d · Riederer P.c · Gerlach M.c · Becker S.b · Oertel W.H.a · Höglinger G.U.aaExperimental Neurology, Department of Neurology, Philipps University Marburg, Marburg, bCentral Division of Analytical Chemistry, Research Center Juelich, Juelich, and cClinical Neurochemistry, Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany; dINSERM UMR679, Experimental Neurology and Therapeutics, Hôpital de la Salpetrière et eUniversité Pierre et Marie Curie Paris 6, Paris, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 29, 2007
Issue release date: June 2007
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 2
ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)
For additional information: https://www.karger.com/NDD
Abstract
Background: Neuromelanin-containing neurons of the substantia nigra are highly vulnerable to degenerate in Parkinson’s disease. Inhibition of the respiratory chain or formation of reactive oxygen species (ROS) by intracellular neuromelanin and triggering of inflammatory processes by extracellular neuromelanin emanating from melanized neurons after their demise are thought to be causally implicated in the high vulnerability of melanized neurons. Objective: We addressed the direct effect of purified neuromelanin on mitochondrial complex I activity, and its influence on ROS production and survival of primary mesencephalic neurons in the presence or absence of glia. Methods: Neuromelanin was isolated from midbrain of postmortem human brains. The content in iron and other elements was measured by inductively coupled mass spectrometry. The effect of neuromelanin on mitochondrial complex I activity was analyzed in post-nuclear extracts. Primary neuronal enriched and neuron-glia mixed cultures from midbrain were treated with different concentrations of neuromelanin. The generation of ROS was determined by fluorochrome detection. MAP2-positive and TH-positive neuronal viability was analyzed. Results: Neuromelanin did not affect complex I activity, but concentration-dependently increased ROS production in neurons and reduced the number of MAP2-positive and TH-positive cultured neurons. Glia protected neurons against the neuromelanin toxicity. Conclusion: Extracellular neuromelanin is detrimental to neurons implicating a mechanism of intracellular ROS production, but not complex I inhibition. ROS formation may be catalyzed by iron, which was sensitively identified in purified neuromelanin (3.3 mg/g). Importantly, we demonstrate that glial cells have the potential to mitigate the neurotoxic effect of neuromelanin.
© 2007 S. Karger AG, Basel
Related Articles:
References
-
Youdim MB, Ben-Shachar D, Riederer P: The enigma of neuromelanin in Parkinson’s disease substantia nigra. J Neural Transm 1994;43(suppl):113–122.
- Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P: Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson’s disease. Neurotox Res 2003;5:35–44.
- Zecca L, Zucca FA, Wilms H, Sulzer D: Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578–580.
- Hirsch E, Graybiel AM, Agid YA: Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson’s disease. Nature 1988;334:345–348.
- Damier P, Hirsch EC, Agid Y, Graybiel AM: The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson’s disease. Brain 1999;122:1437–1448.
- Double KL, Zecca L, Costi P, Mauer M, Griesinger C, Ito S, Ben-Shachar D, Bringmann G, Fariello RG, Riederer P, Gerlach M: Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000;75:2583–2589.
- Zecca L, Gallorini M, Schunemann V, Trautwein AX, Gerlach M, Riederer P, Vezzoni P, Tampellini D: Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem 2001;76:1766–1773.
- Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R: Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson’s disease. FASEB J 2003;17:500–502.
- Tribl F, Gerlach M, Marcus K, Asan E, Tatschner T, Arzberger T, Meyer HE, Bringmann G, Riederer P: ‘Subcellular proteomics’ of neuromelanin granules isolated from the human brain. Mol Cell Proteomics 2005;4:945–957.
- Kawamoto JC, Barrett JN: Cryopreservation of primary neurons for tissue culture. Brain Res 1986;384:84–93.
- Höglinger GU, Carrard G, Michel PP, Friguet B, Hirsch EC: Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson’s disease. J Neurochem 2003;86:1297–1307.
-
Zecca L, Tampellini E, Rizzio E, Giaveri G, Gallorini M: The determination of iron and other metals by INNA in cortex, cerebellum and putamen of human brain and in their neuromelanins. J Radioanalyt Nucl Chem 2001;248:129–131.
External Resources
- Double KL, Gerlach M, Schünemann V, Trautwein AX, Zecca L, Gallorini M, Youdim MBH, Riederer P, Ben-Shachar D: Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol 2003;66:489–494.
- Bridelli MG, Tampellini D, Zecca L: The structure of neuromelanin and its iron binding site studied by infrared spectroscopy. FEBS Lett 1999;457:18–22.
- Zecca L, Mecacci C, Seraglia R, Parati E: The chemical characterization of melanin contained in substantia nigra of human brain. Biochim Biophys Acta 1992;1138:6–10.
- Loschen G, Flohe L, Chance B: Respiratory chain linked H(2)O(2) production in pigeon heart mitochondria. FEBS Lett 1971;18:261–264.
- Boveris A, Oshino N, Chance B: The cellular production of hydrogen peroxide. Biochem J 1972;128:617–630.
- Liu Y, Fiskum G, Schubert D: Generation of reactive oxygen species by the mitochondrial electron transport chain. J Neurochem 2002;80:780–787.
-
Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD: Mitochondrial complex I deficiency in Parkinson’s disease. Lancet 1989;i:1269.
External Resources
- Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD: Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 1990;55:2142–2145.
- Kropf AJ, Bunker BA, Eisner M, Moss SC, Zecca L, Stroppolo A, Crippa PR: X-ray absorption fine-structure spectroscopy studies of Fe sites in natural human neuromelanin and synthetic analogues. Biophys J 1998;75:3135–3142.
- Dzierzega-Lecznar A, Kurkiewicz S, Stepien K, Chodurek E, Wilczok T, Arzberger T, Riederer P, Gerlach M: GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra. J Am Soc Mass Spectrom 2004;15:920–926.
- Ostergren A, Svensson AL, Lindquist NG, Brittebo EB: Dopamine melanin-loaded PC12 cells: a model for studies on pigmented neurons. Pigment Cell Res 2005;18:306–314.
- Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL: Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem 2005;95:599–608.
- Bachur NR, Gordon SL, Gee MV, Kon H: NADPH cytochrome P-450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA 1979;76:954–957.
- Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, Frankel WN, Bronson RT, Ackerman SL: The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 2002;419:367–374.
- Lipton SA, Bossy-Wetzel E: Dueling activities of AIF in cell death versus survival: DNA binding and redox activity. Cell 2002;111:147–150.
- Wakamatsu K, Fujikawa K, Zucca F, Zecca L, Ito S: The structure of neuromelanin as studied by chemical degradative methods. J Neurochem 2003;86:1015–1023.
- Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, Zucca FA: The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004;101:9843–9848.
- Zecca L, Shima T, Stroppolo A, Goj C, Battiston GA, Gerbasi R, Sarna T, Swartz HM: Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 1996;73:407–415.
- Rao KS, Hegde ML, Anitha S, Musicco M, Zucca FA, Turro NJ, Zecca L: Amyloid beta and neuromelanin – toxic or protective molecules? The cellular context makes the difference. Prog Neurobiol 2006;78:364–373.
- Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007;8:57–69.
-
Aimi Y, McGeer PL: Lack of toxicity of human neuromelanin to rat brain dopaminergic neurons. Parkinson Rel Disord 1996;2:69–74.
External Resources
- Ishida Y, Nagai A, Kobayashi S, Kim SU: Upregulation of protease-activated receptor-1 in astrocytes in Parkinson disease: astrocyte-mediated neuroprotection through increased levels of glutathione peroxidase. J Neuropathol Exp Neurol 2006;65:66–77.
- Desagher S, Glowinski J, Premont J: Astrocytes protect neurons from hydrogen peroxide toxicity. J Neurosci 1996;16:2553–2562.
- Dhandapani KM, Hadman M, De Sevilla L, Wade MF, Mahesh VB, Brann DW: Atrocyte protection of neurons: role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway. J Biol Chem 2003;278:43329–43339.
- Saavedra A, Baltazar G, Santos P, Carvalho CM, Duarte EP: Selective injury to dopaminergic neurons up-regulates GDNF in substantia nigra postnatal cell cultures: role of neuron-glia crosstalk. Neurobiol Dis 2006;23:533–542.
- Michel PP, Marien M, Ruberg M, Colpaert F, Agid Y: Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes. J Neurochem 1999;72:2074–2082.
Article / Publication Details
Published online: June 29, 2007
Issue release date: June 2007
Number of Print Pages: 9
Number of Figures: 4
Number of Tables: 2
ISSN: 1660-2854 (Print)
eISSN: 1660-2862 (Online)
For additional information: https://www.karger.com/NDD
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
PubMed ID
